カリオファーム:第3相XPORT-EC-042試験、PFSエンドポイント未達

The Phase 3 XPORT-EC-042 trial of selinexor maintenance in TP53 wild-type endometrial cancer did not meet its primary PFS endpoint. A numerical trend favoring selinexor was seen in the mITT population (HR 0.76, p=0.0791) but did not reach statistical significance. The company will present full data at a future medical meeting and states that results do not affect other ongoing selinexor trials.

主要事実

提出: 2026年7月31日 12:30
イベント: トップライン結果
方向: ネガティブ
企業: KPTIカリオファルム
アセット: selinexor
出典: SEC 8-K
信頼度: 出典あり
ITT登録: 257
mITT登録: 220

出典の抜粋

8-K false 0001503802 0001503802 2026-07-30 2026-07-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2026 Karyopharm Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36167 26-3931704 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 85 Wells Avenue , 2nd Floor Newton , Massachusetts 02459 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (617) 658-0600 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-

SEC 8-K